VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

David D. Chang, MD, PhD
Published: Tuesday, Jun 25, 2013

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

There are three TRINOVA studies, Chang says, which Amgen has been involved with for years. In the TRINOVA-1 trial, patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer were randomized to receive trebananib (AMG 386) or placebo in combination with weekly paclitaxel chemotherapy.

Trebananib is a peptibody designed to block angiopoietins 1 and 2, and therefore blocking angiogenesis, Chang says.

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

There are three TRINOVA studies, Chang says, which Amgen has been involved with for years. In the TRINOVA-1 trial, patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer were randomized to receive trebananib (AMG 386) or placebo in combination with weekly paclitaxel chemotherapy.

Trebananib is a peptibody designed to block angiopoietins 1 and 2, and therefore blocking angiogenesis, Chang says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x